Atishoo! Atishoo! They all cash in

A flu epidemic is good news for a company with a 'wonder drug' in the lab. Liz Hunt looks behind the hype

Nobles at the courts of Queen Elizabeth I and Mary Queen of Scots referred to it as the "newe acquaintance". In 1568, a Thomas Willis said that it appeared to be sent "by some blast of stars", and in 1775 it was reported that 20,000 people had been "seized in one night".

More than 200 years later influenza is still grabbing headlines. One of the most common and debilitating of global infections, the virus can have a devastating impact on industry, schools and hospitals. Millions of pounds have been invested in trying to beat it, but so far it has defied the best efforts of scientists. So when a new flu cure is mooted, it is guaranteed column inches.

With an eagle eye on its share price, Glaxo Wellcome has seized the opportunity presented by reports of a pre-Christmas epidemic to hype a new potential flu drug, one which is scarcely out of the laboratory.

The company says that a poor flu season last year hampered the development of the compound, known as GG167. There were too few cases to try it on. But this year, the company says confidently, the surge in cases of flu and flu-like illness now being reported has presented the ideal conditions for large-scale clinical trials. It predicts approval from regulatory authorities for a nasal spray or inhalation as early as 1997, with sales in its first year in excess of pounds 200m.

Such confidence in a drug which has been tested in just a handful of human volunteers so far - very few of whom actually had flu - has alarmed drug industry observers and leading scientists. They see a trend developing in which British pharmaceutical companies, once a model of caution, are making claims for compounds still in the preliminary stages of development.

The reasons are clear. The executives of British companies are desperate to retain their dominant position in the global market place, and time is running out. They need new products to replace their top sellers - drugs like Zantac, an anti-ulcer treatment and the best selling drug in the world, but one which loses its patent exclusivity in less than two years' time. Drug companies believe that the "hyping" strategy persuades shareholders to keep the faith. British Biotech, a relatively new company, last week saw its share price shoot up by more than 50 per cent after releasing results of a new anti-cancer drug. The drug, marimastat, had been tested in just 94 patients for one month only.

GG167 is certainly a novel approach to combating the influenza virus. The computer-designed drug does not kill it, but appears to stop the virus in its tracks. It blocks an enzyme, neuraminidase, which is essential for the release of the virus from infected human cells in the nasal passage and the airways of the lungs. The theory is that the immune system will then "mop up" these infected cells and so prevent their spread through the rest of the body.

Peter Collins, a scientist at Monash University in Melbourne, Australia, is credited with discovering GG167 in the mid-Eighties. However, the compound belongs to a much older group of chemicals developed in the Sixties by Peter Palese, a chemist in Vienna. He recognised their potential as anti- viral drugs, but Collins, an X-ray crystallographer, was the one to "fine- tune" the original molecule until it was specific for strains A and B of the flu virus - the most common strains in circulation - sticking to them at a particular point and inhibiting neuraminidase.

Palese's molecule was boat-shaped and fitted a groove in the viral structure neatly enough, according to Professor John Oxford, a leading virologist at the Royal London Hospital in Whitechapel. "What Collins did was add a little oar shape to the molecule so that it fitted even better and had greater efficacy against the virus," he explains.

In the test tube and in laboratory animals, GG167 has proved successful, but in humans there is little in the way of conclusive evidence. Other similar neuraminidase inhibitors are being developed in labs around the world, and there is fierce competition to be first on the market. However, many virologists believe that a simpler back-to-basics approach, now being applied to the Aids virus, is the only way forward against flu: better drugs to treat the symptoms are a more cost-effective option than millions of pounds being invested in potential cures.

But other doctors point to an existing drug as the most exciting prospect for treating influenza A, the most dangerous strain of the virus and the one associated with most fatalities. The drug is amantadine, made by Ciba Geigy and sold as Symmetrel. It is better known as a treatment for Parkinson's disease but its value in flu is widely recognised by those in the know. It is, however, underused because few GPs have heard of it and the Department of Health is not keen to promote it. Flu vaccination for those at particular risk stretches the NHS budget enough as it is. The department has, according to some doctors, overemphasised its side-effects, described as an excess of "jittery" feelings.

A related drug, rimantadine, would reduce these minor side-effects even further, it is claimed. It is rarely used in the West but doctors in the former Soviet Union have regularly prescribed it and have a wide base of patient experience. A few Western drug companies have expressed interest but refuse to comment on its potential as a flu treatment just yet. It is, however, a more realistic option than a hi-tech, state-of-the-art compound which, so far, has proved itself effective at relieving flu symptoms only in laboratory rats and mice.

PROMOTED VIDEO
Have you tried new the Independent Digital Edition apps?
News
ebooksAn unforgettable anthology of contemporary reportage
Arts and Entertainment
Rita Ora will replace Kylie Minogue as a judge on The Voice 2015
tv
Life and Style
tech
Life and Style
Alan Turing, who was convicted of gross indecency in 1952, was granted a royal pardon last year
life
Arts and Entertainment
Sheridan Smith as Cilla Black and Ed Stoppard as her manager Brian Epstein
tvCilla Episode 2 review: Grit under the glamour in part two of biopic series starring Sheridan Smith
Life and Style
life
Arts and Entertainment
Tennis player Andy Murray's mum Judy has been paired with Anton du Beke for Strictly Come Dancing. 'I'm absolutely delighted,' she said.
tvJudy Murray 'struggling' to let Anton Du Beke take control on Strictly
Life and Style
Vote with your wallet: the app can help shoppers feel more informed about items on sale
lifeNew app reveals political leanings of food companies
Arts and Entertainment
The cover of Dark Side of the Moon
musicCan 'The Endless River' carry on the tradition? See for yourself
Sport
New Zealand fly-half Aaron Cruden pictured in The Zookeeper's Son on a late-night drinking session
rugby
Extras
indybest
Voices
A new app has been launched that enables people to have a cuddle from a stranger
voicesMaybe the new app will make it more normal to reach out to strangers
Arts and Entertainment
Salmond told a Scottish television chat show in 2001that he would also sit in front of a mirror and say things like,
tvCelebrity Trekkies from Alex Salmond to Barack Obama
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Semi Senior Accountant - Music

£30000 - £35000 per annum: Sauce Recruitment: A successful, Central London bas...

English teachers required in Lowestoft

£21000 - £35000 per annum: Randstad Education Cambridge: Qualified English tea...

Business Development Director - Interior Design

£80000 - £100000 per annum + competitive + bonus + benefits: Sauce Recruitment...

Sales Director, Media Sponsorship

£60000 - £65000 per annum: Sauce Recruitment: A globally successful media and ...

Day In a Page

Secret politics of the weekly shop

The politics of the weekly shop

New app reveals political leanings of food companies
Beam me up, Scottie!

Beam me up, Scottie!

Celebrity Trekkies from Alex Salmond to Barack Obama
Beware Wet Paint: The ICA's latest ambitious exhibition

Beware Wet Paint

The ICA's latest ambitious exhibition
Pink Floyd have produced some of rock's greatest ever album covers

Pink Floyd have produced some of rock's greatest ever album covers

Can 'The Endless River' carry on the tradition?
Sanctuary for the suicidal

Sanctuary for the suicidal

One mother's story of how London charity Maytree helped her son with his depression
A roller-coaster tale from the 'voice of a generation'

Not That Kind of Girl:

A roller-coaster tale from 'voice of a generation' Lena Dunham
London is not bedlam or a cradle of vice. In fact it, as much as anywhere, deserves independence

London is not bedlam or a cradle of vice

In fact it, as much as anywhere, deserves independence
Vivienne Westwood 'didn’t want' relationship with Malcolm McLaren

Vivienne Westwood 'didn’t want' relationship with McLaren

Designer 'felt pressured' into going out with Sex Pistols manager
Jourdan Dunn: Model mother

Model mother

Jordan Dunn became one of the best-paid models in the world
Apple still coolest brand – despite U2 PR disaster

Apple still the coolest brand

Despite PR disaster of free U2 album
Scottish referendum: The Yes vote was the love that dared speak its name, but it was not to be

Despite the result, this is the end of the status quo

Boyd Tonkin on the fall-out from the Scottish referendum
Manolo Blahnik: The high priest of heels talks flats, Englishness, and why he loves Mary Beard

Manolo Blahnik: Flats, Englishness, and Mary Beard

The shoe designer who has been dubbed 'the patron saint of the stiletto'
The Beatles biographer reveals exclusive original manuscripts of some of the best pop songs ever written

Scrambled eggs and LSD

Behind The Beatles' lyrics - thanks to Hunter Davis's original manuscript copies
'Normcore' fashion: Blending in is the new standing out in latest catwalk non-trend

'Normcore': Blending in is the new standing out

Just when fashion was in grave danger of running out of trends, it only went and invented the non-trend. Rebecca Gonsalves investigates
Dance’s new leading ladies fight back: How female vocalists are now writing their own hits

New leading ladies of dance fight back

How female vocalists are now writing their own hits